Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis
about
Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsLow-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.How to manage the transplant question in myelofibrosis.Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisInfluence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Allogeneic stem cell transplantation for myelofibrosis in 2012.Myelofibrosis 2012: it's complicated.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.
P2860
Q26863610-16EB84B1-3D10-4B3B-A66B-4B5C458FAB1FQ34860077-CAAD2C19-D318-4541-9E61-1CD0DC3ACD21Q35463268-D7E1CB5E-3F0F-4EFE-9B22-71546E5776D6Q35608022-5E65948B-FE6D-4C3A-AC97-2C94E5590086Q35865676-1D9BD70E-6751-4F88-B302-F0206C1880D9Q36206849-57985B66-1118-4902-9D35-7A1D1B7B27CFQ36474050-8B844827-0D84-433C-B8F7-C16F722EF606Q36777485-81E7CAB5-7485-4676-9321-B7E1A0EDD0B4Q37998567-0B617D4B-D586-4C81-B0EC-79832F61DE18Q38095967-F67A5580-37F1-4CB4-9555-1D26D327720EQ38202155-A887B2AA-5B2A-456D-A30B-E577C926813F
P2860
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@ast
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@en
type
label
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@ast
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@en
prefLabel
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@ast
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@en
P2093
P2860
P1476
Improved outcomes using tacrol ...... as treatment of myelofibrosis
@en
P2093
Anthony S Stein
David S Snyder
Firoozeh Sahebi
Joycelynne Palmer
Nyana Vora
Ryotaro Nakamura
Stephen J Forman
Vinod Pullarkat
P2860
P304
P356
10.1016/J.BBMT.2009.09.020
P577
2009-09-26T00:00:00Z